Osivax Partners with CEPI to Advance T-cell Immunity using World-First Adjuvant Library Access to CEPI’s Adjuvant Library to assess dose-sparing potential of adjuvanted formulations of OVX836 vaccine in flu pandemic settings Potential to maximize vaccine supply and broaden global access in emergencies, while maintaining a non-adjuvanted OVX836 core development path Lyon, France and Liège, Belgium – …
Tag archives: OVX836
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836 Target enrollment of 2,850 healthy volunteers completed across multiple European countries Topline data read-out expected by mid-2026, subject to influenza circulation during the winter season Lyon, France and Liège, Belgium – December 09, 2025 – Osivax, a biopharmaceutical company developing …
I4ID 2025
Lyon, France – PosterMathilde Jarlier, Immuno R&D engineer, to present a poster entitled “Role of Anti-Nucleoprotein Antibodies in Influenza Protection: Implications for the Development of OVX836, a Broad-Spectrum Influenza Vaccine”. Charlotte Primard, Head of Non-clinical Immunology at Osivax, to present “OVX836, a Nucleoprotein-based vaccine under clinical development, offers protection Against Highly Pathogenic Avian Influenza Viruses …
10th ESWI 2025
Valencia, Spain – Oral PresentationCharlotte Primard, Head of Non-clinical Immunology at Osivax, to provide an update on OVX836 as part of a presentation entitled “OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models”.
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836 Phase 2b to assess efficacy, safety, and immunogenicity 2,850 participants to be enrolled across European countries Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating …
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
Osivax Receives $19.5M BARDA Award to Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836 Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has …
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 – Osivax, a biopharmaceutical company …
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …
World Vaccine Congress Washington 2025
Washington, DC, USA – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Advancing Influenza Prevention: Latest Clinical Insight on OVX836, a Broad-spectrum T-Cell Influenza Vaccine”.
I4ID 2024
Lyon, France – PosterSéverine Valsesia, Immuno R&D engineer, to present a poster entitled “A mix of OVX836, a NP-based influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice”. François Fasquelle, Clinical Immunology Project Manager, to present a poster entitled “OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic …